Anzeige
Mehr »
Login
Dienstag, 21.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Die Wachstumsgeschichte: Analysten sehen kurzfristige +37 %-Chance bei diesem europäischen Marktführer
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0CBCK | ISIN: US02043Q1076 | Ticker-Symbol: DUL
Tradegate
20.05.24
12:37 Uhr
136,45 Euro
-1,15
-0,84 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
ALNYLAM PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ALNYLAM PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
137,40138,2522:12
136,80138,8522:00

Aktuelle News zur ALNYLAM PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoALNYLAM PHARMACEUTICALS, INC. - 8-K, Current Report2
Fr(ALNY) - Analyzing Alnylam Pharmaceuticals' Short Interest1
DoMarket Whales and Their Recent Bets on ALNY Options2
MiPro Research: Wall Street eyes Alnylam's RNAi therapeutics potential4
06.05.Pro Research: Wall Street eyes Alnylam's RNAi therapeutics potential6
03.05.Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y1
02.05.Alnylam Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary3
02.05.Alnylam Pharmaceuticals Inc. Q1 Loss Decreases, beats estimates219WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals Inc. (ALNY) revealed Loss for first quarter that decreased from last year and beat the Street estimates.The company's bottom line totaled -$65.94...
► Artikel lesen
02.05.ALNYLAM PHARMACEUTICALS, INC. - 10-Q, Quarterly Report2
02.05.ALNYLAM PHARMACEUTICALS, INC. - 8-K, Current Report2
02.05.Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity266CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended...
► Artikel lesen
30.04.Alnylam, Medison Expand Partnership To Market RNAi Therapeutics In Addnl. LATAM And APAC Markets275WASHINGTON (dpa-AFX) - Tuesday, Alnylam Pharmaceuticals Inc. (ALNY) announced that it has expanded its multi-regional partnership with Medison Pharma to market RNAi Therapeutics in selected...
► Artikel lesen
30.04.Medison Pharma; Alnylam Pharmaceuticals: Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia220The expanded partnership will allow Alnylam and Medison to help accelerate access for patients in multiple regions under one global allianceMedison, the creator and leader of the multi-regional...
► Artikel lesen
22.04.Ahead of Alnylam's key heart disease readout, experts say Pfizer rival would be hard to displace28
19.04.How Is The Market Feeling About Alnylam Pharmaceuticals?2
08.04.Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data4
07.04.Alnylam Presents Positive Results From KARDIA-2 Phase 2 Study Of Zilebesiran At ACC711SOUTH SAN FRANCISCO (dpa-AFX) - Alnylam Pharmaceuticals, Inc. (ALNY) presented KARDIA-2 Phase 2 study results of zilebesiran for the treatment of hypertension at the 2024 American College of...
► Artikel lesen
02.04.$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today7
02.04.Pro Research: Wall Street eyes Alnylam's RNAi therapeutics potential3
18.03.Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years8
Seite:  Weiter >>
94 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1